Cerebrolysin
Neuropeptide Preparation | Neurological Recovery
Community Research
Join others researching Cerebrolysin — share findings, ask questions, and learn from real experiences
Standardized neuropeptide preparation containing bioactive peptides and amino acids exhibiting neurotrophic and neuroprotective properties for stroke recovery, traumatic brain injury, and cognitive enhancement. Used clinically in 50+ countries.
Mechanism of Action
IV/IM administration provides optimal bioavailability and brain penetration of neuropeptides and neurotrophic factors.
Key Benefits
- Direct brain delivery
- Standardized dosing
- Extensive clinical evidence
- Ready-to-use formulation
- Used clinically in 50+ countries
Bioactive peptide mixture Complex or non-standard sequence format
Cognitive
- Alzheimer's Disease
Meta-analyses show modest cognitive improvements, though clinical significance remains debated.
- Vascular Dementia
Multiple RCTs demonstrate significant ADAS-cog and CIBIC+ improvements.
- Post-Stroke Cognitive Recovery
Large meta-analysis shows significant NIHSS improvements; other studies found no functional benefit.
Neuroprotection
- Acute Stroke
Largest meta-analysis (1,879 patients) shows NIHSS benefits; independent analysis found no mRS improvement.
- Traumatic Brain Injury
Multiple trials including CAPTAIN series confirm GCS/GOS improvements.
- Subarachnoid Hemorrhage
Pilot trial shows promising 6-month outcomes; requires larger confirmatory studies.
Recovery
- Motor Function Recovery
Some studies show enhanced recovery; results vary significantly between trials.
- Neurological Function
Early administration within 72 hours shows better outcomes than delayed treatment.
Primary administration route with well-established protocols for direct brain delivery via IV/IM.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Small Volume IV | Up to 10mL | Once daily | Undiluted IV slow push over 3 minutes |
| Intramuscular | Up to 5mL | Once daily | Undiluted IM injection over 3 minutes |
| Acute Stroke | 20-50mL | Once daily for 10-21 days | IV infusion (diluted to 100mL minimum) |
| Traumatic Brain Injury | 20-50mL | Once daily for 7-30 days | IV infusion (diluted to 100mL minimum) |
| Alzheimer's Disease | 10-30mL | 5 days weekly for 4 weeks | IV injection/infusion (2-4 cycles yearly) |
| Vascular Dementia | 10-30mL | 5 days weekly for 4 weeks | IV injection/infusion (2-4 cycles yearly) |
Reconstitution Instructions
- Cerebrolysin ampoules (5, 10, or 20 mL)
- Saline, Ringer solution, or 5% glucose (minimum 100 mL for infusion)
- Disposable one-way IV infusion sets and cannulas
- Sterile syringes and alcohol swabs
- 1 Break ampoule and extract Cerebrolysin immediately before use
- 2 For direct injection: Up to 10 mL IV undiluted (slow 3 minutes) or 5 mL IM
- 3 For infusion: Dilute 10-50 mL to minimum 100 mL with compatible solution
- 4 Start infusion immediately after dilution—infuse within 15 minutes
- 5 Flush IV catheter with sodium chloride before and after administration
- 6 Use disposable one-way infusion sets; discard after use
Safe combination with no significant interactions; both support cognitive function.
No interactions reported; may have synergistic cognitive effects in Alzheimer's treatment.
Potential additive neurotropic effects; monitor for enhanced antidepressant effects.
May have additive neurological effects; requires careful monitoring.
Contraindicated per prescribing information; do not mix in same infusion.
Should not be mixed in same IV infusion per official guidelines.
Compatibility issues; do not mix in same IV infusion.
Both enhance neurotrophic factors; potential additive effects—start with lower doses.
Initial neuroprotective effects; possible mild side effects (dizziness, agitation)
Neurological improvements become apparent; cognitive function may begin to improve
Continued recovery; motor function improvements in stroke/TBI patients
Sustained benefits; cognitive enhancement plateaus in chronic conditions
Common Side Effects
- Generally well tolerated
- Possible mild dizziness or agitation in early treatment
Stop Signs - Discontinue if:
- Severe allergic reactions (anaphylaxis, severe rash)
- New onset seizure activity
- Significant cardiovascular events during administration
- Severe renal dysfunction or worsening kidney function
Contraindications
- Epilepsy
- Severe renal insufficiency
- History of severe allergic reactions to porcine products
Good Signs
- Clear amber solution from reputable source
- Room temperature storage ≤25°C
- Protected from light in original carton
- Authorized EVER Pharma distributor
Warning Signs
- Some published studies have been retracted due to research misconduct; rely on independent meta-analyses
Bad Signs
- Frozen product or improper storage—never freeze
- Mixing with incompatible solutions (amino acids, vitamins, cardiovascular medications)
- CAPTAIN II Trial - Traumatic Brain Injury(2020)
Randomized controlled trial demonstrating efficacy and safety in moderate-severe TBI with improved GCS and GOS scores.
- Nine-Trial Stroke Meta-Analysis - Positive Results(2017)
Largest positive meta-analysis showing significant neurological improvements in 1,879 stroke patients with NNT=7.7.
- Conflicting Stroke Meta-Analysis - Neutral Results(2017)
Independent meta-analysis of 1,779 patients found no significant benefits in functional outcomes (mRS/BI).
- TBI Systematic Review - Positive Outcomes(2023)
Analysis of 8,749 TBI patients across 10 studies confirms statistically significant GCS/GOS improvements.
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.